Welcome to our dedicated page for BriaCell Therapeutics Warrant news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics Warrant stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) has announced the pricing of a $8.5 million offering of 12,325,000 common shares or pre-funded warrants at $0.69 per share. The offering, priced at-the-market under Nasdaq rules, is expected to close on September 12, 2024. ThinkEquity is acting as the sole placement agent. BriaCell intends to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives. The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC. BriaCell is a clinical-stage biotechnology company developing novel immunotherapies for cancer care.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) has reported positive overall survival data from its Phase 2 clinical study of Bria-IMT™ in combination with an immune checkpoint inhibitor for late-stage metastatic breast cancer. The study showed a median overall survival of 15.6 months in patients treated since 2022, compared to 6.7-9.3 months reported in literature for similar patients. This represents a significant improvement over the previously reported 13.4 months median overall survival in December 2023.
The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients, with an average of 6 prior treatments. The Bria-IMT™ regimen showed no drug-related discontinuations to date. BriaCell is currently conducting a Phase 3 pivotal study using the same Bria-IMT™ formulation in metastatic breast cancer patients.
BriaCell Therapeutics Corp. (NASDAQ: BCTX, TSX: BCT) has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with the FDA for Bria-PROS+™, its personalized off-the-shelf immunotherapy for advanced prostate cancer. The FDA has waived the requirement for animal toxicology and pharmacokinetic studies, simplifying the development pathway. This feedback provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+™. The company views this as a major step in developing a potential novel approach for prostate cancer, which remains the second-leading cause of cancer death in American men. These interactions also inform the development of BriaCell's proprietary Bria-OTS+™ platform for other cancers.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT), a clinical-stage biotechnology company focused on novel immunotherapies for cancer care, has announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, TX.
The presentation is scheduled for Friday, November 8, 2024, from 9:00 am to 7:00 pm CST at the George R. Brown Convention Center. BriaCell's Chief Scientific Officer, Dr. Miguel Lopez-Lago, expressed excitement about presenting their data at this prestigious conference. The company aims to continue investigating novel targeted immunotherapy candidates for breast and prostate cancer patients. After the presentation, the poster will be available on BriaCell's website.
BriaCell Therapeutics Corp. (Nasdaq: BCTX) reports significant progress in its Phase 2 study of the Bria-IMT™ regimen for metastatic breast cancer. A patient with ADC-resistant cancer showed a 9.1-month progression-free survival (PFS), quadrupling the PFS of similar studies. This patient, who had failed 8 prior treatments, experienced a marked reduction in tumor size, including the disappearance of a temporal lobe lesion.
The company's President and CEO, Dr. William V. Williams, expressed optimism about replicating these results in their ongoing Phase 3 study. Dr. Giuseppe Del Priore, Chief Medical Officer, highlighted the treatment's favorable safety and tolerability profile. This development represents a potential breakthrough in treating metastatic breast cancer, an area with significant unmet medical needs.
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer patients, showing a median PFS of 4.1 months, nearly double the rate of similar studies. Dr. Saranya Chumsri and Dr. Carmen Calfa highlighted the potential for Bria-IMT™ to address unmet medical needs in advanced breast cancer. Further, BriaCell's pivotal Phase 3 study will compare Bria-IMT™ with Treatment of Physician's Choice (TPC).
BriaCell Therapeutics (NASDAQ: BCTX, BCTXW; TSX: BCT), a clinical-stage biotechnology company, has initiated a first-in-human Phase 1/2 study for its immunotherapy, Bria-OTS™, targeting advanced metastatic breast cancer. The study aims to evaluate the safety and efficacy of Bria-OTS™ both as a monotherapy and in combination with the PD-1 inhibitor tislelizumab. This milestone follows the successful completion of Institutional Review Board (IRB) and Clinical Trial Site Agreement (CTA) processes, along with FDA authorization for Investigational New Drug (IND) filings. BriaCell's leadership believes the personalized approach of Bria-OTS™ could lead to more potent and durable responses, potentially improving patients' quality of life and extending survival. The treatment's off-the-shelf nature is expected to provide rapid therapeutic intervention, important for patients with advanced metastatic breast cancer.
BriaCell Therapeutics has announced a clinical supply agreement with BeiGene to assess the safety and efficacy of BriaCell’s Bria-OTS™ immunotherapy in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for treating advanced, heavily pretreated metastatic breast cancer. This Phase 1/2 trial will initially focus on Bria-OTS™ alone in breast cancer, expanding to a combination therapy with tislelizumab. BriaCell aims to extend this therapy to prostate and other cancers. The Bria-OTS™ platform builds on Bria-IMT™, which has shown benefits in patients with CNS metastases and resistance to checkpoint inhibitors and ADCs.
BriaCell Therapeutics announced promising clinical data for its lead product candidate, Bria-IMT™, at the ASCO 2024 Annual Meeting. Key results include a median progression-free survival (PFS) of 4.1 months in ADC-resistant advanced breast cancer patients, which is double the PFS of patients in similar studies. The clinical benefit rate was 55% across HR+, HER2+, and TNBC disease types. Additionally, the therapy achieved an 83% intracranial objective response rate in patients with CNS metastases. The treatment was well-tolerated with no related discontinuations or cases of interstitial lung disease. These findings will be presented through various sessions during the ASCO event held from May 31 to June 4, 2024.
BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.
FAQ
What is the current stock price of BriaCell Therapeutics Warrant (BCTXW)?
What is BriaCell Therapeutics Corp focused on?
What is the significance of BriaVax vaccine?
What upcoming clinical trial is BriaCell preparing for?
What is Bria-OTS and its purpose?
Where is BriaCell Therapeutics Corp headquartered?
How can I contact BriaCell for more information?
Who is the Media Relations contact for BriaCell?
How can investors get in touch with BriaCell?
What type of clinical trial is BriaCell conducting for breast cancer?
What is BriaCell's outlook on expanding their technology?
